title: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
abstract: Early in the development of respiratory syncytial virus (RSV) vaccines severe disease occurred in children after receipt of formalin-inactivated RSV vaccine. Continuing efforts to develop an appropriately attenuated and immunogenic live RSV vaccine have given opportunities to assure that live vaccines are safe through surveillance of children after vaccination. In the present study, the rate of RSV-associated upper respiratory tract illness in 388 children was lower in RSV vaccinated children than in controls (14% versus 20% in a 6-24 month old group and 16% versus 25% in infants). Additionally, there was no evidence that vaccination predisposed to more severe lower respiratory tract illness. Thus infection with a series of live attenuated RSV vaccines did not result in enhanced disease upon infection with wild type RSV. The impact of RSV during this surveillance will inform the design of future efficacy studies with RSV vaccines.
authors.affiliation: Vanderbilt University, Nashville, TN, USA. peter.wright@vanderbilt.edu
authors.forename: Peter F
authors.initials: PF
authors.lastname: Wright
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Karron
authors.forename: Robert B
authors.initials: RB
authors.lastname: Belshe
authors.forename: Jian R
authors.initials: JR
authors.lastname: Shi
authors.forename: Valerie B
authors.initials: VB
authors.lastname: Randolph
authors.forename: Peter L
authors.initials: PL
authors.lastname: Collins
authors.forename: Alice F
authors.initials: AF
authors.lastname: O'Shea
authors.forename: William C
authors.initials: WC
authors.lastname: Gruber
authors.forename: Brian R
authors.initials: BR
authors.lastname: Murphy
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D006801:Humans; D007223:Infant; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D012449:Safety; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology
chemical_list: D000914:Antibodies, Viral; D022261:Respiratory Syncytial Virus Vaccines; D014613:Vaccines, Attenuated